Infusion Specialists的动态

More than 6 million Americans are currently living with Alzheimer's, and that number is expected to nearly double by 2050, reaching almost 13 million. To optimize the care of patients living with this debilitating condition, Spotlight On Alzheimer’s Disease features insights from leading neurologists and allied healthcare professionals on the latest diagnostic and treatment advances. Stay informed about cutting-edge research and innovative treatment approaches to enhance patient care and quality of life. Stay ahead in Alzheimer's management: https://ow.ly/2I2k50SL32r #AlzheimersDisease #Neurology #HealthcareInnovation #MedicalResearch #PatientCare #DementiaAwareness

Frontotemporal Dementia is a rapid and devastating form of dementia for which there are currently no approved treatments. ? #FTD affects the lives of patients and their families in profound ways, making normal life all but impossible. ? Recognising the signs and symptoms is crucial so that families can be supported and can connect with the FTD community to ensure the highest quality of life possible. ? At Vesper Bio, we have developed a potentially disease-modifying treatment for this devastating condition, #VES001, which is currently in Phase I clinical trials. Delivered orally, VES001 allows for dosing at home, thus avoiding the trauma of repeated hospital visits for patients already in significant distress. ? To learn more about what we do, visit our website. ? #neurodegeneration #biotech #frontotemporaldementia #Alzheimer's

Anyone who has experienced the dementia journey via a loved one (like me) or otherwise knows the devastation and will appreciate what we're solving for and why this matters. Status quo care typically ends at diagnosis leaving patients and their care partners to their own devices to figure out what to do. Through our Mayo Clinic partnership, we've pioneered the first clinically validated early intervention for patients with MCI and early dementia and their care partners. Coupled with our CMS GUIDE program we can now precision manage and support patients/care partners via #virtualcare throughout this complicated journey - solving access challenges and completely changing the disease process trajectory and patient/care partner experience while improving every measure of outcome. Thank you Nuvance Health for your vision and partnership to support the 100,000+ people in the communities you serve who can now count on your innovative leadership to bring them a unique and game-changing solution for this condition. Thank you Paul Wright, Alex Mosteanu, MD, FACP, Amy Kohn Scott Costley, MD, Amy A. Forni #neuroglee, #nuvancehealth #NeurogleeConnect #VirtualCare #Dementia #DigitalHealth #MildCognitiveImpairment #DementiaCare #CognitiveCare #Neurology #Healthequity #Patientcare #CaregiverSupport #CareAtHome #Alzheimers #valuebaseddementiacare #CMSGUIDE #valuebasedcare

When I talked about the importance of addressing Alzheimer’s agitation a while ago, now I want to share something really promising. The chart shows the great progress being made with AXS-05, a new treatment specifically targeting agitation in Alzheimer’s patients. What really stands out to me is how the AXS-05 group showed a much bigger improvement in agitation symptoms compared to the placebo and bupropion groups. From these studies, it shows how AXS-05 is making real progress in reducing symptoms over just a few weeks. With ongoing trials and the FDA Breakthrough Therapy Designation, it feels like we’re getting closer to a treatment that could really improve the quality of life for Alzheimer’s patients and their caregivers. #Alzheimer #BioTech #AXS05

As a family physician who lost my grandmother to Alzheimer's in 2019, I'm cautiously optimistic about this new blood test for Alzheimer's disease. The reported 88-92% diagnostic accuracy is promising, especially for improving early detection in primary care settings. The ability to identify Alzheimer's pathology through a simple blood test could be transformative, potentially allowing for earlier interventions and better patient care planning. However, I'm mindful of the test's limitations - it's most useful for those already showing cognitive impairment and may not be as effective for subjective cognitive decline. While this test could enhance our diagnostic capabilities, I believe it should complement, not replace, our current clinical evaluations. The human element - understanding a patient's full history, lifestyle, and concerns - remains crucial. We must also consider the ethical implications of early diagnosis, especially given limited treatment options. Moving forward, I'm eager to see how this test performs across diverse populations and in real-world clinical settings. As we advance in Alzheimer's detection, we must ensure our care approaches evolve in tandem, focusing on holistic support for patients and families facing this challenging diagnosis. Article: https://lnkd.in/dxvRXkfi

For Some Alzheimer’s Patients, Vision Problems May be an Early Warning: A large study published in the journal Lancet Neurology, brings attention to a lesser-known variant of Alzheimer's disease called posterior cortical atrophy. The study outlines the diagnosis of PCA, its biological markers, the demographics of its patients, and the symptoms of the syndrome. Early symptoms can include?difficulties reading and driving and difficulty judging distances.?The study authors said they hope greater awareness of the syndrome will help doctors diagnose it earlier.?Learn more?here: https://lnkd.in/eFa26avS

Great points from both The Lancet and World Stroke Organization highlighting discussions from the 77th World Health Assembly highlighting the need for policy makers to enhance access to quality acute stroke care to reduce non-communicable disease-related death and disability. As the market-leading digital clinical pathway for stroke care, Capture Stroke enhances access by providing analytics and care alerts, empowering clinicians to deliver timely, evidence-based interventions for better patient outcomes. #StrokeCare #HealthPolicy #AcuteCare #CaptureStroke #PatientOutcomes

From the last update of the #Spanish Society of Neurology consensus: "[C]onsidering early initiation of [high-efficacy] #DMTs can optimize clinical outcomes, delay disease progression, and improve the quality of life and long-term prognosis for [#MultipleSclerosis] patients. We join other voices advocating that initiating #heDMT early is the optimal strategy for achieving the most favorable long-term outcomes for individuals with MS. However, the decision to initiate heDMT early is complex and depends on several factors, such as the expertise of the neurologist with these therapies, long-term safety data, prognostic factors, the information that patients have and their preferences, availability of therapies and disease monitoring, local regulatory requirements, and national and international guidelines." https://lnkd.in/gvVu77Tj Celia Oreja-Guevara, Dr. José Meca Lallana

I find it inspiring to witness the significant advancements in drug development that are shaping our community. This article emphasizes the importance of research and highlights the hope it brings to families facing Alzheimer’s. #DrugDevelopment #ClinicalTrials?

Are you up to date on the latest advancements in multiple sclerosis MS care? Spotlight on Multiple Sclerosis is your go-to resource for cutting-edge news and clinical breakthroughs. Join leading neurologists and allied healthcare professionals as they share research updates and novel insights on evidence-based practices for MS. Learn how to slow disease course, treat relapses, manage symptoms, and improve patient function and safety. Enhance your practice today: https://ow.ly/Jpcb50Sc02W #MultipleSclerosis #Neurology #HealthcareProfessionals #MSResearch #PatientCare